Molecular Partners reports key financials for FY 2018 and corporate highlights for Q4 2018: Company positioned for growth following positive phase 3 abicipar data and validation of DARPin® platform through Amgen collaboration
Zurich-Schlieren, Switzerland, February 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage
biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today
announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter
2018. The fourth quarter was marked by positive phase 3 efficacy data presented for abicipar as well
as the initiation of a strategic collaboration with Amgen in the field of immuno-oncology, two key
milestones for the company.